Evidence map›Paper›PMID 32063229›Full record

Observational studyBMC medicine2020

C-reactive protein as a potential biomarker for disease progression in dengue: a multi-country observational study.

Nguyen Lam Vuong, Huynh Thi Le Duyen, Phung Khanh Lam, Dong Thi Hoai Tam, Nguyen Van Vinh Chau, Nguyen Van Kinh, Ngoun Chanpheaktra, Lucy Chai See Lum, Ernesto Pleités, Nick Keith Jones and 7 more

Open access · goldAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in BMC medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 3 pooled it
8.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 3 syntheses or guidelines pooled it, 76 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Observational
  6. Observational
  7. Article
  8. Observational
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 10 institutions in 8 countries.

Nguyen Lam VuongOxford University Clinical Research Unit, Wellcome Trust Asia Programme, Ho Chi Minh City, Vietnam.
Huynh Thi Le DuyenOxford University Clinical Research Unit, Wellcome Trust Asia Programme, Ho Chi Minh City, Vietnam.
Phung Khanh LamOxford University Clinical Research Unit, Wellcome Trust Asia Programme, Ho Chi Minh City, Vietnam.
Dong Thi Hoai TamOxford University Clinical Research Unit, Wellcome Trust Asia Programme, Ho Chi Minh City, Vietnam.
Nguyen Van Vinh ChauHospital of Tropical Diseases, Ho Chi Minh City, Vietnam.
Nguyen Van KinhNational Hospital for Tropical Diseases (NHTD), Hanoi, Vietnam.
Ngoun ChanpheaktraAngkor Hospital for Children, Siem Reap, Cambodia.
Lucy Chai See LumUniversity of Malaya Medical Centre, Kuala Lumpur, Malaysia.
Ernesto PleitésHospital Nacional de Niños Benjamin Bloom, San Salvador, El Salvador.
Nick Keith JonesUniversity of Cambridge, Cambridge, UK.
Cameron Paul SimmonsOxford University Clinical Research Unit, Wellcome Trust Asia Programme, Ho Chi Minh City, Vietnam.
Kerstin RosenbergerSection of Clinical Tropical Medicine, Department of Infectious Diseases, Heidelberg University Hospital, Heidelberg, Germany.
Thomas JaenischSection of Clinical Tropical Medicine, Department of Infectious Diseases, Heidelberg University Hospital, Heidelberg, Germany.
Christine HalleuxUNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases, World Health Organization, Geneva, Switzerland.
Piero Luigi OlliaroCentre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Bridget WillsOxford University Clinical Research Unit, Wellcome Trust Asia Programme, Ho Chi Minh City, Vietnam.
Sophie YacoubOxford University Clinical Research Unit, Wellcome Trust Asia Programme, Ho Chi Minh City, Vietnam. syacoub@oucru.org.ORCID 0000-0002-2910-7819
Oxford University Clinical Research Unit · VNAngkor Hospital for Children · KHHeidelberg University · DEHospital for Tropical Diseases · VNUniversity of Oxford · GBHospital Nacional de Niños Bloom · SVUniversity Malaya Medical Centre · MYUniversity of Cambridge · GBUniversity of Medicine and Pharmacy at Ho Chi Minh City · VNWorld Health Organization · CH

Funding

European Union FP7-281803 IDAMSWorld Health Organization 001World Health Organization UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases
6 · The paper itself

Abstract

backgroundDengue infection can cause a wide spectrum of clinical outcomes. The severe clinical manifestations occur sufficiently late in the disease course, during day 4-6 of illness, to allow a window of opportunity for risk stratification. Markers of inflammation may be useful biomarkers. We investigated the value of C-reactive protein (CRP) measured early on illness days 1-3 to predict dengue disease outcome and the difference in CRP levels between dengue and other febrile illnesses (OFI).

methodWe performed a nested case-control study using the clinical data and samples collected from the IDAMS-consortium multi-country study. This was a prospective multi-center observational study that enrolled almost 8000 participants presenting with a dengue-like illness to outpatient facilities in 8 countries across Asia and Latin America. Predefined severity definitions of severe and intermediate dengue were used as the primary outcomes. A total of 281 cases with severe/intermediate dengue were compared to 836 uncomplicated dengue patients as controls (ratio 1:3), and also 394 patients with OFI.

resultsIn patients with confirmed dengue, median (interquartile range) of CRP level within the first 3 days was 30.2 mg/L (12.4-61.2 mg/L) (uncomplicated dengue, 28.6 (10.5-58.9); severe or intermediate dengue, 34.0 (17.4-71.8)). Higher CRP levels in the first 3 days of illness were associated with a higher risk of severe or intermediate outcome (OR 1.17, 95% CI 1.07-1.29), especially in children. Higher CRP levels, exceeding 30 mg/L, also associated with hospitalization (OR 1.37, 95% CI 1.14-1.64) and longer fever clearance time (HR 0.84, 95% CI 0.76-0.93), especially in adults. CRP levels in patients with dengue were higher than patients with potential viral infection but lower than patients with potential bacterial infection, resulting in a quadratic association between dengue diagnosis and CRP, with levels of approximately 30 mg/L associated with the highest risk of having dengue. CRP had a positive correlation with total white cell count and neutrophils and negative correlation with lymphocytes, but did not correlate with liver transaminases, albumin, or platelet nadir.

conclusionsIn summary, CRP measured in the first 3 days of illness could be a useful biomarker for early dengue risk prediction and may assist differentiating dengue from other febrile illnesses.

Indexed as

AdolescentAdultBiomarkersCase-Control StudiesChildChild, PreschoolC-Reactive ProteinDisease ProgressionFemaleHumansMaleMiddle AgedPrognosisProspective StudiesSevere DengueYoung AdultBiomarkersC-Reactive ProteinBiomarkerC-reactive proteinDengueOther febrile illnessPrognosis

Identifiers

PMID32063229
PMCPMC7025413
OpenAlexW3009180299

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.